Antibody binding sites specific for EGFRvIII

US10273309B2 · kind B2 · utility

Assignee

• AFFEMED GMBH · DE

Inventors

• Kristina Ellwanger · Heidelberg, DE
• Uwe Reusch · Maikammer, DE
• Ivica Fucek · Hattersheim, DE
• Stefan Knackmuss · Plankstadt, DE
• Vera Molkenthin · Tännesberg, DE
• Melvyn Little · Büdelsdorf, DE
• Eugene Zhukovsky · West Hollywood, US

Key dates

• Filing date: Feb 4, 2016
• Grant date: Apr 30, 2019
• Expiry date: Apr 4, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application describes binding proteins that specifically bind to EGFRvIII and multispecific binding proteins that specifically bind to EGFRvIII and CD3. Further described is a multispecific tandem diabody that binds to EGFRvIII and CD3. Further described are highly cytotoxic EGFRvIII/CD3 bispecific tandem diabody for recruiting T cells to specifically and potently kill several types of solid tumor cancer.